

Durkin Brian L
Form 3
October 24, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Durkin Brian L

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH

CHICAGO,Â ILÂ 60064

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

10/16/2018

3. Issuer Name **and** Ticker or Trading Symbol
AbbVie Inc. [ABBV]

4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

____ Director ____ 10% Owner
__X__ Officer ____ Other
(give title below) (specify below)
VP, Controller

5. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group
Filing(Check Applicable Line)
__X__ Form filed by One Reporting
Person
____ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common stock, \$0.01 par value

4,251

D

Â

Common stock, \$0.01 par value

253

I

By spouse ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

4. Conversion
or Exercise
Price of
Derivative

5. Ownership
Form of
Derivative
Security:

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Durkin Brian L - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option (right to buy) <u>(2)</u>	Â <u>(2)</u>	07/24/2026	Common stock	5,240	\$ 64.12	D	Â
Option (right to buy) <u>(3)</u>	Â <u>(3)</u>	02/15/2027	Common stock	7,180	\$ 61.36	D	Â
Option (right to buy) <u>(4)</u>	02/15/2019	02/14/2028	Common stock	3,110	\$ 114.36	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Durkin Brian L 1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064	Â	Â	Â VP, Controller	Â

Signatures

Steven Scrogam, attorney-in-fact for Brian L. Durkin

10/24/2018

****Signature of Reporting Person**

Date _____

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reporting person disclaims beneficial ownership of all securities held by his spouse.

Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under

(2) Rule 16b-3. The option became exercisable as to 1,747 shares on 7/25/2017 and as to 1,746 shares on 7/25/2018, and becomes exercisable as to 1,747 shares on 7/25/2019.

Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under

(3) Rule 16b-3. The option became exercisable as to 2,394 shares on 2/16/2018, and becomes exercisable as to 2,393 shares on 2/16/2019 and as to 2,393 shares on 2/16/2020.

Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under

(4) Rule 16b-3. The option becomes exercisable in annual increments of 1,037 shares on 02/15/2019, 1,036 shares on 02/15/2020, and 1,037 shares on 02/15/2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.